Enabling protein platform: MarraBio’s proprietary Caf1 technology enables low-cost, high-performance multimeric proteins for cell culture, cultivated meat, and therapeutics.

Targeting high value sectors: Focused on high-growth markets demanding biomaterials—cell culture reagents and cultivated meat.

Defensive IP: Spun out from decades of Newcastle Uni research; holds exclusive patents in the US and Japan.

Scalable & animal-free: E. coli-based bioprocessing delivers cost-effective, sustainable, and scalable manufacturing.

Strong exit potential: strong return profile, with clear revenue, licensing, and M&A exit opportunity in a highly acquisitive space.